Division plan of Synektik SA
Spin-off of R&D activities
Agreeing of the Issuer's division plan
The Management Board of Synektik SA announces that on 27 March 2025 it adopted a directional resolution on division of the Company by transferring a portion of its assets, in the form of an organized part of its enterprise including the Cardiotracer and the Centre for Research on New Particels to another company, Syn2bio.
Business of Syn2bio
The purpose of Syn2bio business:
- search for innovative new pharmaceutical compounds which, following selection and conduct of the full process of preclinical and clinical trials, will be subject to the process of introduction and registration on selected geographical markets, verification of candidates for clinical trials, and preparation of the necessary medical, qualitative and registration procedures connected with the process of placing of the given medical product on the market,
- research work on an innovative tracer used for diagnostic tests on cardiac disorders in the area of myocardial perfusion (the Cardiotracer project).
Documents
| Name | Action |
|---|---|
| ESPI Report 23/2026 on approval by the Registry Court of the Issuer’s division published on 30 March 2026 (English) | Download |
| ESPI Report 18/2026 with attachment on resolutions regarding the division of Synektik SA adopted by the Extraordinary Shareholder Meeting, published on 19 March 2026 (English) | Download |
| ESPI Report 14/2026 on the second notification of intent to carry out a division of Synektik SA published on 18 February 2026 (English) | Download |
| ESPI Report 12/2026 on the first notification of intent to carry out a division of Synektik SA published on 3 February 2026 (English) | Download |
| ESPI Report 44/2025 on the auditor's report on the audit of the Division Plan published on 3 September 2025 (English) | Download |
| Division Plan published by Synektik and Syn2bio on 23 July 2025, updated on 2 September 2025 (Polish) | Download |
| Auditor's report on the audit of the Division Plan published on 2 September 2025 (Polish) | Download |
| Division Plan published by Synektik and Syn2bio on 23 July 2025 (Polish) | Download |
| Management Boards statement regarding the divison published on 23 July 2025 (Polish) | Download |
| ESPI Report 37/2025 on agreeing and adoption of the division plan of Synektik SA published on 23 July 2025 (English) | Download |
| ESPI Report 23/2025 on adoption of directional resolution on division of Synektik SA published on 27 March 2025 (English) | Download |
Press releases
| Name | Action |
|---|---|
| 30 March 2026: The division of Synektik is complete—the court has registered the issue of Syn2bio shares | Download |
| 19 March 2026: Synektik shareholders have unanimously approved the division of the company and spinoff of the cardiotracer project to Syn2bio | Download |
| 12 March 2026: KNF has approved the Syn2bio prospectus. The debut on the WSE is planned for April | Download |
| 17 November 2025: Synektik edges closer to demerger as Syn2bio files prospectus with KNF | Download |
| 23 July 2025: Synektik one step closer to planned division | Download |
| 27 March 2025: Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE | Download |
